Luxmed Onkologia sp. z o. o. ( Site 0653)

Warsaw, Masovian Voivodeship 01-748

0 studies enrolling now · 1 studies all time

What they study most

High-risk Non-muscle Invasive Bladder Cancer

Studies at this site

• Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) — Running, not enrolling